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Abstract
Background
Although intensive statin therapy is recommended for high risk patients, evidence of its
benefit in patients with stable coronary artery disease (CAD) and very low low-density lipo-
protein-cholesterol (LDL-C) has been very rare. In this study, we investigated whether
higher statin intensity reduces cardiovascular risks in this population.
Methods
In this retrospective study, a total of 5234 patients with stable CAD were screened at three
tertiary hospitals in Korea; 449 patients (mean age: 65 years, male: 69%) with LDL-C <80
mg/dL were finally analyzed. The statin intensities were classified according to the 2013
American College of Cardiology/American Heart Association guidelines. Patients who
received statins equivalent to or weaker than atorvastatin 10 mg (group 1) were compared
with those who took statins equivalent to or stronger than atorvastatin 20 mg (group 2). The
impact of statin intensity on major adverse cardiac events (MACE) was evaluated during
follow-up.
Results
Group 1 and group 2 consisted of 181 patients (40.3%) and 268 patients (59.7%), respec-
tively. The mean LDL-C level decreased to 52 and 57 mg/dL in group 1 and group 2,
respectively, during follow-up. In a median follow-up of 4.5 years, patients of group 2 had a
lower incidence of MACE (30 [16.6%] vs. 12 [4.5%], p <0.001), which were mostly related
to a lower incidence of coronary revascularization. Cox proportional hazard analyses
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identified the statin intensity of group 2 (adjusted hazard ratio: 0.25, confidence interval:
0.11–0.55, p <0.001) and the baseline high-density lipoprotein-cholesterol level as inde-
pendent determinants of MACE.
Conclusion
This study provides evidence that higher intensity statins are beneficial for cardiovascular
outcomes in patients with stable CAD and very low LDL-C. Statins equivalent to or stronger
than atorvastatin 20 mg are more effective than lower intensity statins.
Introduction
Most recent guidelines on lipid management emphasize the aggressive lowering of low-density
lipoprotein-cholesterol (LDL-C) levels in high-risk groups [1,2]. In particular, early pharmaco-
logic therapy has been recommended for very high-risk patients, such as those with acute coro-
nary syndrome [3]. The rationale of this strategy is based on previous studies in which the
extent of the clinical benefit derived from statin therapy correlated with the level of patient risk
[4]. The benefits of statins have been proven in high-risk patients, irrespective of baseline
LDL-C levels [5]. For instance, statins reduced cardiovascular events even in patients with
mean LDL-C levels of 116 mg/dL [6]. For high-risk patients, more intensive lipid reduction
resulted in a more favorable clinical outcome [5]. This has been demonstrated repeatedly, espe-
cially in patients with acute coronary syndrome [7–9].
On the other hand, although intensive statin therapy is also recommended for patients with
stable coronary artery disease (CAD), evidence of its benefits in this population is less com-
mon. In particular, data on the effects of statins in patients with stable CAD and very low base-
line LDL-C levels are very rare. In the Treating to New Targets (TNT) study, a greater clinical
benefit was observedwith intensive statin therapy in patients with stable CAD. However, the
required LDL-C level for inclusion in the study was<130 mg/dL, and no further analysis was
conducted in patients with very low LDL-C level [10].
Statins are also widely used in East Asian countries. However, sufficient data have not been
published on the clinical benefits of statins in Asians. In addition, an Asian background is one
of the predisposing factors for statin-related adverse reactions [1]. Although physicians are
concerned about the safety of statins when prescribing high intensities of these drugs to Asians,
the optimal statin dose for this population, with different cardiovascular risks, is uncertain.
The aims of this study were to investigate 1) whether the statin intensity affects cardiovascu-
lar risk in Korean patients with stable CAD and very low LDL-C (<80 mg/dL) and if so, 2)
which intensity can better reduce the risk.
Methods
Study population
The Institutional ReviewBoard (IRB) of SeveranceHospital, Seoul, Korea approved this study.
Informed consent was waived by the IRB for the following reasons: 1) the research involves no
more than minimal risk to the subjects; 2) the waiver does not reversely affect the rights and
welfare of the subjects; and 3) the research could not be practicably carried out without the
waiver. Three hospitals in Korea participated in this study: SeveranceHospital, Seoul; National
Health Insurance Service Ilsan Hospital, Goyang; and Korea University Guro Hospital, Seoul.
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A total of 5234 consecutive patients who visited each hospital fromMay 2005 to February 2014
and had a diagnosis of stable CAD were initially screened. The diagnosis of stable CAD was
made if patients had chest discomfort or pain typical of myocardial ischemia and coronary ste-
nosis. When their symptom was not typical, diagnosis was made by further examination,
including treadmill exercise test or nuclear perfusion scan. The angiographic criterion was ste-
nosis>50% in more than one coronary artery. We excluded individuals with a history of myo-
cardial infarction. Patients with LDL-C80 mg/dL, who were taking lipid-lowering agents at
the time of blood testing, or who did not take statins after the diagnosis of CAD were excluded.
In addition, subjects who did not exhibit consistent statin intensity for at least 80% of the fol-
low-up periodwere also excluded. Consistent statin intensity is defined as the maintenance of
the same statin intensity during the study period. Finally, 449 patients were included in the
analysis (Fig 1).
Study protocol
This was a retrospective observational study. Clinical data, including demographic variables,
medical history, and medication use, were obtained by trained interviewers. Blood samples
were collected after a 12-h fast and analyzed by the local laboratories. The study population
was treated by using standard medical therapies, including statins, according to the physicians’
discretion. The subjects were classified according to the statin intensity received during80%
of the follow-up period. The statin intensity was classified according to the 2013 American Col-
lege of Cardiology (ACC)/AmericanHeart Association (AHA) guidelines.
Most of our study population were prescribedwith moderate intensity statins, and no
patients received low intensity statins. To determine whether there was a difference in the clini-
cal benefits experiencedby patients receiving different doses of moderate intensity statins, we
divided these patients into two groups: patients with atorvastatin 10 mg or similar (group 1)
and those with atorvastatin 20 mg or similar. Because the numbers of patients who took high
intensity statins were too small to be analyzed separately, they were combined with those
received atorvastatin 20 mg or similar (group 2). We listed the frequency, dose, and treatment
duration of statins in each group in S1 Table.
The patients were followed every 3–6 months in the outpatient clinic at each center. They
underwent lipid profile examination every 3–12 months. Changes in LDL-C levels were
Fig 1. Patient screening, exclusion, and enrollment.
doi:10.1371/journal.pone.0166246.g001
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calculated as follows: (final value−baseline value) / baseline value x100 (%). Clinical outcome
data were obtained in outpatient clinics, by medical record reviews, or by means of telephone
contact. The outcome variable was major adverse cardiac events (MACE), defined as the com-
posite of cardiovascular death, nonfatal myocardial infarction, and coronary revascularization.
A death was considered of cardiovascular origin if the cause was associated with myocardial
infarcion or ischemia, arrhythmia, heart failure, or stroke, or if the death was sudden and
unexpected.
Statistical analysis
Continuous variables with little skewing are reported as means ± standard deviations. Those
that do not have a normal distribution are reported as medians (interquartile ranges). The tri-
glyceride levels did not show normal distribution. In the Kolmogorov-Smirnov tests, the p val-
ues for the baseline and follow-up triglycerides of group 1 were 0.16 and 0.12, respectively,
whereas those of group 2 were 0.20 and 0.22, respectively. Therefore, we used log-transformed
values for triglycerides in our analysis. Categorical variables are presented as frequencies and
percentages. The patients’ clinical and laboratory variables were compared by using Student’s
t-test and the chi-square test. A paired t-test was used to compare parameters before and after
drug treatment within each group. As the triglyceride levels did not show a normal distribu-
tion, both theWilcoxon signed-rank test for the median and the paired t-test for log triglycer-
ides were used. Cumulative survival curves for each group were made by using the Kaplan-
Meier method and compared by using the log-rank test. The determinants of MACE were
identified through a univariate Cox regression analysis. Age, sex, and variables with p value
<0.15 in the analysis were entered into a multivariate analysis in a stepwise manner. The num-
ber of events was small with regard to the number of variables entered into the multivariate
analysis, and this might lead to model over-fitting. To reduce this limitation in the analysis, we
performed propensity score matching. Age, sex, hypertension, diabetes mellitus, smoking,
LDL-C level, and coronary artery bypass graft (CABG)were used as matching variables. Haz-
ard ratios and 95% confidence intervals were calculated. All analyses used two-tailed tests with
a significance level of 0.05. SPSS version 17.0 (SPSS Inc, Chicago, IL, USA) was used for the
analyses.
Results
Clinical characteristics
Among 449 patients, group 1 included 181 patients (40.3%) who received atorvastatin 10 mg
or similar. Group 2 included 217 patients (48.3%) who received atorvastatin 20 mg or similar
and 51 patients (10.3%) who received atorvastatin 40–80 mg or similar. No patient was pre-
scribedwith low intensity statins. Patients’ ages, sexes, and medical histories did not differ
between groups 1 and 2. The proportions of patients prescribedwith each concomitant medi-
cation were similar among the groups. Of the total subjects, 410 (91.3%) underwent percutane-
ous coronary intervention, while 39 (8.7%) underwent CABG. The rates of each
revascularizationdid not differ between the statin intensity groups (Table 1).
Change in lipid profiles and clinical outcomes
The patients were followed up for a median of 4.5 years. At baseline, the mean LDL-C values
were similar between the groups (65 mg/dL in group 1 and 2). Conversely, the mean follow-up
LDL-C levels ranged from 52 to 57 mg/dL and were significantly lower in group 2 (p<0.001).
Likewise, the percentages changes in LDL-C level were greater in group 2 (p = 0.02). At follow-
Statin Intensity in Stable CAD and Very Low LDL-C
PLOS ONE | DOI:10.1371/journal.pone.0166246 November 8, 2016 4 / 10
up, group 2 demonstrated lower total cholesterol and similar triglyceride levels compared with
those of group 2 (Table 2).
During follow-up, 42 patients (9.4%) experiencedMACE, including 4 cardiovascular deaths,
2 nonfatal myocardial infarction, and 36 coronary revascularizations. Patients in group 2 had a
significantly lower incidence of these events (30 [16.6%] vs 12 [4.5%], p<0.001), which were
mostly associated with a lower incidence of coronary revascularization (27 [14.9%] vs 9 [3.4%],
p<0.001) (Table 3). The Kaplan-Meier survival curves also revealed a higher event-free sur-
vival rate in this group (p<0.001; Fig 2).
Determinants of MACE
The results of univariate and multivariate Cox proportional hazard analyses of MACE are pre-
sented in Table 4. Older age was related to MACE, whereas a higher baseline high-density lipo-
protein-cholesterol level was associated with a lower risk of MACE. With respect to statin
intensity, group 2 (statins equivalent to or stronger than atorvastatin 20 mg) was associated
with a lower risk of MACE, compared with group 1 (statins equivalent to atorvastatin 10 mg).
After adjusting for variables derived from univariate analyses, the statin intensity of group 2
(adjusted HR: 0.25, p<0.001) and the baseline high-density lipoprotein-cholesterol (adjusted
HR: 0.96, p = 0.04) were found to be independent determinants of MACE.
Discussion
The present study demonstrated that 1) statin intensity is an independent determinant of
MACE in patients with stable CAD, even when the baseline LDL-C is<80 mg/dL, and 2)
Table 1. Baseline characteristics of the patients.
Group 1 (n = 181) Group 2 (n = 268) p
Age, years 65±10 65±11 0.83
Male 121 (66.9) 189 (70.5) 0.47
Medical history
Hypertension 131 (72.4) 189 (70.5) 0.75
Diabetes mellitus 66 (36.5) 118 (44.0) 0.12
Current smoker 38 (21.0) 45 (16.8) 0.27
Body mass index, kg/m2 24.7±3.8 24.6±3.9 0.65
Number of diseased vessels
1 115 (50.7) 120 (44.8) 0.42
2 59 (26.0) 80 (29.9)
3 53 (23.3) 69 (25.4)
Medications
Antiplatelet agents 181 (100) 268 (100) 1.00
β-blockers 109 (60.2) 147 (54.9) 0.29
Calcium channel blockers 77 (42.5) 97 (36.2) 0.20
ACE inhibitors or ARBs 89 (49.2) 126 (47.0) 0.70
Revascularization
PCI 170 (93.9) 240 (89.6) 0.13
CABG 11 (6.1) 28 (10.4)
Median follow up, years (IQR) 4.9 (2.3, 6.5) 4.2 (2.3, 6.0) 0.09
Values are presented as mean ± SD, or n (%) unless otherwise stated; ACE: angiotensin converting enzyme;
ARB: angiotensin receptor blocker; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; IQR: interquartile range
doi:10.1371/journal.pone.0166246.t001
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Table 2. Changes in lipid profiles.
Group 1 (n = 181) Group 2 (n = 264) Pa
Total cholesterol Before 151±37 152±45 0.83
After 129±37 119±25 0.003
pb <0.001 <0.001
Triglycerides Before 117 (73, 192) 104 (76,150) 0.25
After 97 (74, 144) 102 (72, 127) 0.25
pb <0.001 0.001
LogTriglycerides Before 4.80±0.65 4.71±0.57 0.22
After 4.72±0.58 4.62±0.50 0.79
pb <0.001 0.002
HDL-C Before 42.0±10.7 42.1±10.7 0.94
After 44.6±12.6 42.9±10.1 0.15
pb 0.001 0.34
LDL-C Before 65±13 65±12 0.76
After 57±18 52±15 0.004
pb <0.001 <0.001
% change of LDL-C -7.7±41.9 -16.1±31.0 0.02
Values are presented as mean±SD except triglycerides, which is presented as median (IQR)
a: comparision between groups
b: comparison within a group before and after treatment; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol
doi:10.1371/journal.pone.0166246.t002
Table 3. Incidence of MACE.
Group 1 (n = 181) Group 2 (n = 264) p
MACE, 30 (16.6) 12 (4.5) <0.001
Cardiovascular death 3 (1.7) 1 (0.4) 0.31
Nonfatal MI 0 (0) 2 (0.7) 0.52
Coronary revascularization 27 (14.9) 9 (3.4) <0.001
Values are presented as n (%); MACE: major adverse cardiac events; MI: myocardial infarction
doi:10.1371/journal.pone.0166246.t003
Fig 2. Kaplan-Meier curves for patients classified by statin intensity.
doi:10.1371/journal.pone.0166246.g002
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statins equivalent to or stronger than atorvastatin 20 mg are better in reducing the risk than
lower intensity statins. For the first time, to our knowledge, this study showed the clinical
impact of statin intensity in patients with stable CAD and very low LDL-C level. Furthermore,
our results provide evidence for an appropriate statin strategy in populations for whom further
LDL-C reduction has been empiric and controversial. It is worth noting that the current data
were derived from an East Asian population in whom the safety of statin is of concern and data
on statin doses and clinical outcomes are extremely limited.
The data of patients with stable CAD and very low baseline LDL-C level were the focus and
strength of our study. Studies on the effect of statin or statin intensity in patients with similar
conditions as those in our study have been very scarce. In addition, data from this specific
patient group were either not analyzed, or the sample sizes of the studies were not appropriate
for drawing of conclusions. For instance, the LIPS (Lescol Intervention Prevention Study) trial,
which comprised patients with stable and unstable angina, showed that fluvastatin 80 mg
reducedMACE in the subgroup with LDL-C levels below the median. However, the median
value was 132 mg/dL, and the study did not separately analyze the data of subjects with stable
CAD and low LDL-C levels [11]. In the Heart Protection Study, simvastatin 40 mg reduced
bothmortality and vascular events in subjects with baseline LDL-C<116 mg/dL. However,
patients with stable CAD were a minority in that trial, and the statin effect was not analyzed
separately in that group [6]. The TNT trial was the only study to specifically enroll patients
with stable CAD and compare the effects of different statin doses. It was remarkable that this
study clearly demonstrated the superiority of higher intensity statin in subjects with stable
CAD [10]. Nevertheless, because the TNT trial enrolled patients with baseline LDL-C>130
mg/dL, it is difficult to extrapolate that result to individuals with very low LDL-C levels, such
as those in our study. In an analysis of the CREDO-Kyoto RegistryCohort 2, the authors dem-
onstrated that when compared with standard intensity statins, strong intensity statins were
associated, but not significantly, with better clinical outcomes. Although that rare study had a
similar topic as our study and was also conducted in an Asian population, that study was rather
different from ours in that 1) part of the study subjects experiencedmyocardial infarction; 2)
the mean baseline and follow-up LDL-C were 116–125 and 92–101 mg/dL, respectively; and 3)
statins classified as strong intensity in that study were classified as lower moderate intensity in
Table 4. Determinants of MACE according to Cox proportional hazard analysis.
Unadjusted HR (95% CI) p Adjusted HR (95% CI) p
Age 1.04 (1.00–1.07) 0.03 1.03 (0.99–1.07) 0.11
Male 0.92 (0.48–1.78) 0.80 - - - -
Hypertension 1.01 (0.51–1.98) 0.98 - - - -
Diabetes mellitus 0.87 (0.47–1.63) 0.67 - - - -
Current smoker 0.92 (0.43–2.00) 0.84 - - - -
Log Triglycerides 1.12 (0.64–1.97) 0.68 - - - -
HDL-C 0.96 (0.93–0.99) 0.02 0.96 (0.93–0.99) 0.04
LDL-C 0.99 (0.97–1.01) 0.35 - - - -
CABG 1.37 (0.54–3.50) 0.51 - - - -
Statin intensity
Group 1 Reference - - Reference - -
Group 2 0.31 (0.16–0.61) 0.001 0.25 (0.11–0.55) 0.001
MACE: major adverse cardiac events; HR: hazard ratio; CI: confidence interval; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-
cholesterol; CABG: coronary artery bypass graft
doi:10.1371/journal.pone.0166246.t004
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our current study [12]. Therefore, we can again state that our study provides data for a specific
population in which prior evidence of a benefit of aggressive lipid lowering has been absent.
Group 2 had a mean follow-up LDL-C level of 52 mg/dL and showed significant beneficial
effect, whereas group 1 reached 57 mg/dL. This finding bears similarity to those of the IMPRO-
VE-IT trial (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial), which
recently demonstrated that intensive lowering of LDL-C by adding ezetimibe to statin therapy,
resulted in improved cardiovascular outcomes [13]. Nevertheless, the participants of the study
all experienced acute coronary syndrome, which was a major difference from our study. How-
ever, interestingly, the follow-up LDL-C level in the simvastatin-ezetimibe group was 53.7 mg/
dL and similar to that of group 2 in our study. In this regard, the post-treatment LDL-C levels
of group 2 in our study might provide evidence of a better LDL-C target in patients with stable
CAD as well.
To create a more adequate model, and minimize bias and confounding factors, propensity
score matching was conducted (S2 and S3 Tables). After the matching, the incidence of MACE
remained lower in group 2 (30 [16.6%] vs 6 [3.3%], p<0.001; S4 Table). A log-rank test also
showed better event-free survival in group 2 (p<0.001; S1 Fig). A significant impact of higher
intensity statins was further shown by Cox proportional hazard analysis (HR: 0.25, p = 0.001;
S5 Table). Taken together, the benefit of higher intensity statins was consistent before and after
propensity score matching.
Fifty-one patients took high intensity statins. Because only one patient (2.0%) experienced
MACE during follow-up, this might have influenced the results of our study. However, in an
additional analysis on group 1, group 2 minus the high intensity group, and the high intensity
group separately, the statin intensity of group 2 minus the high intensity group was found to be
a significant determinant of the outcome (data not shown).
Our study had some potential limitations. First, as this study was performed in a retrospec-
tive manner, clinical differences could exist between the groups. In addition, this study design
can make the obtained results weaker. However, we performed propensity score matching to
minimize the methodological limitation (S2–S5 Tables) and found that our major findings did
not change. Second, the composition of MACE in our study could be another limitation.
Although the present study showed a significant impact of statin intensity on MACE, the num-
ber of events was small and most events were coronary revascularizations, that had been driven
by the physician’s choice based on ischemic symptom or objective evidence.Meanwhile, other
harder events were not as frequent during the follow-up. Third, one of the inclusion criteria
was that patients were required to show at least 80% consistency during the follow-up. Thus,
there could have been a potential selection bias for those who were more adherent to treatment
or who were taking the same statin intensity. In addition, not only the benefit but also the risk
induced by a drug are important in the clinical field. Unfortunately, however, collecting data
on adverse events after treatment with statins was difficult in our study, because the events
were not recorded well. In a prior study in the Korean population, treatment-emergent adverse
events tended to be more frequent with higher-dose statins [14]. Meanwhile, most statin-
related adverse events were mild and totally reversible in other Korean studies [15, 16] and the
discontinuation rate of statins has been very low even in patients receiving the maximum avail-
able dose of rosuvastatin [16]. In this regard, although data on drug adverse events were not
available in our study, the risk induced by the effectmight not be very large. However, we can-
not completely rule out the potential risk of drug adverse events in patients prescribedwith
higher dose statins. Fourth, our study was not based on a sufficiently large population. How-
ever, to focus on the purpose of the study, we enrolled specific patients by using strict inclusion
criteria: stable CAD, very low LDL-C level, no lipid-lowering agent at baseline, and consistent
statin intensity. Thus, the final sample size was 449 patients and this is the largest study among
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those that have analyzed this specific group of patients. On the other hand, the current data
indicate that the “high” intensity statin described in 2013 ACC/AHA guidelines has not been
commonly used in CAD patients with very low LDL-C level in Korea. In this regard, our study
was not appropriate for evaluating the effect of high intensity statins.
Our study, which was conducted in an East Asian population, demonstrated that higher
intensity statins produce beneficial cardiovascular outcomes in patients with stable CAD and
LDL-C levels<80 mg/dL. Statins equivalent to or stronger than atorvastatin 20 mg were more
effective than lower intensity statins.
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